[go: up one dir, main page]

PE20140860A1 - Compuestos de pirazol como antagonistas de crth2 - Google Patents

Compuestos de pirazol como antagonistas de crth2

Info

Publication number
PE20140860A1
PE20140860A1 PE2013001586A PE2013001586A PE20140860A1 PE 20140860 A1 PE20140860 A1 PE 20140860A1 PE 2013001586 A PE2013001586 A PE 2013001586A PE 2013001586 A PE2013001586 A PE 2013001586A PE 20140860 A1 PE20140860 A1 PE 20140860A1
Authority
PE
Peru
Prior art keywords
independently
compounds
benzyl
carbonyl
fluoro
Prior art date
Application number
PE2013001586A
Other languages
English (en)
Inventor
Ralf Anderskewitz
Domnic Martyres
Thorsten Oost
Wolfgang Rist
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43799503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140860(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20140860A1 publication Critical patent/PE20140860A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPUESTOS DE PIRAZOL DE FORMULA (Ia) O (Ib) DONDE: Ra Y Rb SON INDEPENDIENTEMENTE H, HIDROXI, ALCOXI C1-C6, ENTRE OTROS, O Ra Y Rb JUNTOS CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN UN GRUPO CARBONILO; Rc Y Rd SON INDEPENDIENTEMENTE H, HALOGENO, HALOALQUILO C1-6, ENTRE OTROS O Rc Y Rd JUNTOS CON EL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN UN GRUPO CARBONILO, ENTRE OTROS; Y1, Y2, Y3, Y4 E Y5 SON INDEPENDIENTEMENTE N Y CRY, DONDE RY ES H, HIDROXI, CIANO, ENTRE OTROS; Z ES O, S, Y NRZ, DONDE RZ ES H, ALQUILO C1-C6 O BENCILO; R1 Y R2 ES INDEPENDIENTEMENTE H, FENILO, NAFTILO, ENTRE OTROS; n ES UN NUIMERO ENTERO ENTRE 0 A 3; R3 SI ESTA PRESENTE ES HALOGENO, ALQUILO C1-C6, ALCOXI C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO (1-(2-FLUORO-4-[(1H-INDOL-2-CARBONIL)AMINO]BENCIL)-3,5-DIMETIL-1H-PIRAZOL-4-IL)ACETICO; ACIDO (1-{4-[(5-FLUORO-3-METILBENZOFURAN-2-CARBONIL)AMINO]BENCIL}-3,5-DIMETIL-1H-PIRAZOL-4-IL)ACETICO; ENTRE OTROS. REFERIDO ADEMAS A FORMULACIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS EN COMBINACION CON UNA O MAS SUSTANCIAS ACTIVAS TAL COMO BETAMIMETICOS, ANTICOLINERGICOS, CORTICOSTEROIDES, ENTRE OTROS
PE2013001586A 2011-01-24 2012-01-20 Compuestos de pirazol como antagonistas de crth2 PE20140860A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11151876 2011-01-24

Publications (1)

Publication Number Publication Date
PE20140860A1 true PE20140860A1 (es) 2014-07-20

Family

ID=43799503

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001586A PE20140860A1 (es) 2011-01-24 2012-01-20 Compuestos de pirazol como antagonistas de crth2

Country Status (35)

Country Link
US (1) US8759386B2 (es)
EP (1) EP2668181B1 (es)
JP (1) JP5695216B2 (es)
KR (2) KR101923365B1 (es)
CN (4) CN104961732B (es)
AP (1) AP3343A (es)
AR (1) AR084916A1 (es)
AU (1) AU2012210718B2 (es)
BR (1) BR112013017570B1 (es)
CA (1) CA2825458C (es)
CL (1) CL2013001945A1 (es)
CO (1) CO6801731A2 (es)
CY (1) CY1116012T1 (es)
DK (1) DK2668181T3 (es)
EA (1) EA022559B1 (es)
EC (1) ECSP13012832A (es)
ES (1) ES2529452T3 (es)
GE (1) GEP20156332B (es)
HR (1) HRP20150069T1 (es)
IL (1) IL226920A (es)
MA (1) MA34838B1 (es)
MX (1) MX342830B (es)
MY (1) MY163012A (es)
PE (1) PE20140860A1 (es)
PH (2) PH12013501356A1 (es)
PL (1) PL2668181T3 (es)
PT (1) PT2668181E (es)
RS (1) RS53785B1 (es)
SG (1) SG192096A1 (es)
SI (1) SI2668181T1 (es)
TN (1) TN2013000280A1 (es)
TW (1) TWI527809B (es)
UA (1) UA109696C2 (es)
UY (1) UY33873A (es)
WO (1) WO2012101043A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
JP5999387B2 (ja) * 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Crth2拮抗薬としてのピラゾール化合物
US20140148492A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Bicyclosubstituted pyrazole compounds for treating hair loss
US20140148484A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
EA202092275A1 (ru) * 2018-03-23 2021-02-09 Палатин Текнолоджиз, Инк. Составы пептидов, специфичных к рецептору меланокортина, и способы доставки в желудочно-кишечный тракт
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
WO2025009852A1 (ko) * 2023-07-03 2025-01-09 주식회사 이노보테라퓨틱스 신규한 피라졸 유도체 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
JP3723071B2 (ja) 1999-11-10 2005-12-07 武田薬品工業株式会社 含窒素5員複素環化合物
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
DE602004011966T2 (de) 2003-10-24 2009-02-12 Glaxo Group Ltd., Greenford Heterocyclylverbindungen
WO2006066879A2 (en) * 2004-12-21 2006-06-29 Devgen N.V. Compounds with kv4 ion channel activity
JP4950542B2 (ja) * 2006-04-07 2012-06-13 岩手東芝エレクトロニクス株式会社 固体撮像装置およびその製造方法
EP2040700B1 (en) 2006-06-06 2010-11-24 Glaxo Group Limited N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration
UA92833C2 (en) * 2006-11-27 2010-12-10 Пфайзер Продактс Инк. Pyrazole analogues
CN101874024A (zh) 2007-09-25 2010-10-27 艾克提麦斯医药品有限公司 作为crth2拮抗剂的2-s-苄基取代的嘧啶
CN101874023A (zh) 2007-09-25 2010-10-27 艾克提麦斯医药品有限公司 作为crth2拮抗剂的烷硫基嘧啶
JP2011088826A (ja) * 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
MX2010014172A (es) * 2008-07-03 2011-02-22 Amira Pharmaceuticals Inc Antagonistas de receptores de prostaglandina d2.
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
JP2012517405A (ja) * 2009-02-09 2012-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器及び胃腸の疾患の治療のための新規医薬組成物
CN108383789A (zh) * 2010-01-27 2018-08-10 艾克提麦斯医药品有限公司 作为crth2拮抗剂的吡唑化合物
WO2012013567A1 (en) * 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical composition for treatment of respiratory and inflammatory diseases
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists

Also Published As

Publication number Publication date
PT2668181E (pt) 2015-02-05
KR20140005931A (ko) 2014-01-15
HK1210467A1 (en) 2016-04-22
BR112013017570B1 (pt) 2022-01-11
CN103339125B (zh) 2015-07-15
IL226920A (en) 2016-11-30
MX342830B (es) 2016-10-14
CN107011332A (zh) 2017-08-04
MA34838B1 (fr) 2014-01-02
PH12013501356A1 (en) 2013-09-02
HRP20150069T1 (hr) 2015-02-27
US20130023576A1 (en) 2013-01-24
AU2012210718B2 (en) 2016-06-02
CN104961732A (zh) 2015-10-07
WO2012101043A1 (en) 2012-08-02
EP2668181A1 (en) 2013-12-04
MY163012A (en) 2017-07-31
BR112013017570A2 (pt) 2016-10-18
MX2013008082A (es) 2013-09-13
CO6801731A2 (es) 2013-11-29
PL2668181T3 (pl) 2015-04-30
ECSP13012832A (es) 2013-09-30
CN104961732B (zh) 2017-07-11
EA022559B1 (ru) 2016-01-29
UY33873A (es) 2012-07-31
CN103339125A (zh) 2013-10-02
TW201245184A (en) 2012-11-16
KR101923365B1 (ko) 2018-11-30
AR084916A1 (es) 2013-07-10
HK1186183A1 (en) 2014-03-07
TWI527809B (zh) 2016-04-01
ES2529452T3 (es) 2015-02-20
CN104628705A (zh) 2015-05-20
CL2013001945A1 (es) 2013-10-25
CA2825458C (en) 2021-01-26
AU2012210718A1 (en) 2013-07-04
EA201300857A1 (ru) 2013-12-30
AP2013006942A0 (en) 2013-06-30
SI2668181T1 (sl) 2015-02-27
JP5695216B2 (ja) 2015-04-01
HK1215247A1 (zh) 2016-08-19
US8759386B2 (en) 2014-06-24
EP2668181B1 (en) 2014-11-05
CN104628705B (zh) 2017-04-12
JP2014502986A (ja) 2014-02-06
GEP20156332B (en) 2015-07-27
KR102251939B1 (ko) 2021-05-14
CN107011332B (zh) 2020-03-13
AP3343A (en) 2015-07-31
UA109696C2 (xx) 2015-09-25
RS53785B1 (sr) 2015-06-30
NZ611695A (en) 2015-04-24
CY1116012T1 (el) 2017-01-25
KR20180129962A (ko) 2018-12-05
SG192096A1 (en) 2013-08-30
PH12018501531A1 (en) 2019-04-08
DK2668181T3 (da) 2015-01-19
CA2825458A1 (en) 2012-08-02
TN2013000280A1 (en) 2014-11-10

Similar Documents

Publication Publication Date Title
PE20140860A1 (es) Compuestos de pirazol como antagonistas de crth2
ES2521596T3 (es) Combinación del compuesto GlyT1 con antipsicóticos
BR112014009146A8 (pt) formulações de etanercepte estabilizadas com aminoácidos
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
CO6382106A2 (es) Nueva composicion a base de acido gamma-hidroxibutirico
PA8828101A1 (es) Compuestos triazina como inhibidores mtor y quinasa p13
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
IN2014DN06169A (es)
TN2011000346A1 (en) Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
CO6541606A2 (es) Espiroindolinona- pirrolidinas
CR10784A (es) Nuevos derivados de aminopirimidina como inhibidores de plki
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR084433A1 (es) Inhibidores de la faah y composiciones farmaceuticas que los contienen
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
MX2012003982A (es) Pirrolidinas n-substituidas.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
CO6362007A2 (es) Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica
AR072726A1 (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
MX2008016558A (es) Preparacion y aplicacion terapéutica de derivados de 2-benzoil-imidazopiridinas.
ECSP12011862A (es) Nueva asociación entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un inhibidor de la acetilcolinesterasa y las composiciones farmacéuticas que la contienen
UA110822C2 (uk) Піперидинілмонокарбонові кислоти як агоністи s1p1-рецепторів
AR049770A1 (es) Derivados de piperidina como moduladores de la actividad de quimioquinas
BR112014013906A8 (pt) ésteres de fosfato aromáticos como componentes de formulação agroquímica
AR071483A1 (es) Derivados de la 1,3- dihidro -2h - pirrolo (3,2-b) piridin-2- ona, su preparacion y sus aplicaciones en terapeutica
MX2015006828A (es) Procedimiento de preparacion de derivados de acido 4-haloalquil-3-mercapto-2 sustituido-hidroxibenzoico.

Legal Events

Date Code Title Description
FG Grant, registration